Merck’s latest trial data show its Covid pill is less effective

Merck & Co. said updated results showed its Covid-19 pill reduced the risk of hospitalization or death among adults with mild to moderate disease by 30%, less than a previous estimate and well below a rival treatment from Pfizer Inc.

Shares of Merck slid 3.4% to $79.46 in pre-market trading, reversing earlier gains, while Pfizer rose 5.9%.

Merck’s latest trial analysis includes data from all enrolled participants, the drugmaker said in a statement Friday. Nine deaths were reported in the placebo group, and one in the group receiving the treatment, called molnupiravir.

The data will be at the center of a Tuesday panel discussion by U.S. Food and Drug Administration advisers regarding its use to treat Covid in high-risk patients.

Merck sought U.S. authorization for molnupiravir, also called Lagevrio, in October after a late-stage study showed it cut the risk of hospitalization or death by around 50% in high-risk patients. Another drug, Pfizer’s Paxlovid, has been submitted for review for use in the same population after showing an 89% reduction.

If authorized by regulators, the pills from Merck and Pfizer are likely to overtake infused drugs monoclonal antibodies from Regeneron Pharmaceuticals Inc. and Eli Lilly & Co. that are more expensive and harder to use.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor